These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11070646)

  • 1. Informed consent for BRCA1 and BRCA2 testing: what clinicians should know about the process and content.
    Miesfeldt S; Jones SM; Cohn WF
    J Am Med Womens Assoc (1972); 2000; 55(5):275-9. PubMed ID: 11070646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing for inherited susceptibility to breast cancer: a survey of informed consent forms for BRCA1 and BRCA2 mutation testing.
    Durfy SJ; Buchanan TE; Burke W
    Am J Med Genet; 1998 Jan; 75(1):82-7. PubMed ID: 9450863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic predisposition to breast and ovarian cancer: a case study.
    Amlung S; Huelsman K; Skinn B
    AACN Clin Issues; 1998 Nov; 9(4):555-62. PubMed ID: 9855865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast & ovarian cancer. Issues in risk assessment.
    Caro SW
    Adv Nurse Pract; 1999 Aug; 7(8):26-32; quiz 33-4. PubMed ID: 10745719
    [No Abstract]   [Full Text] [Related]  

  • 7. Deleterious mutations of both BRCA1 and BRCA2 in three siblings.
    Loader S; Rowley PT
    Genet Test; 1998; 2(1):75-7. PubMed ID: 10464601
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 testing: weighing the demand against the benefits.
    Devilee P
    Am J Hum Genet; 1999 Apr; 64(4):943-8. PubMed ID: 10090879
    [No Abstract]   [Full Text] [Related]  

  • 10. First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm.
    Arver B; Borg A; Lindblom A
    Genet Test; 2001; 5(1):1-8. PubMed ID: 11336395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
    Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
    JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex decision-making for BRCA1/2 carriers.
    Matloff ET
    Cancer J Sci Am; 1999; 5(5):266-8. PubMed ID: 10526666
    [No Abstract]   [Full Text] [Related]  

  • 13. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
    Vaziri SA; Krumroy LM; Rostai M; Casey G
    Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
    Lerman C; Biesecker B; Benkendorf JL; Kerner J; Gomez-Caminero A; Hughes C; Reed MM
    J Natl Cancer Inst; 1997 Jan; 89(2):148-57. PubMed ID: 8998184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten novel BRCA1 and BRCA2 mutations in breast and/or ovarian cancer families from northern Germany.
    Kiechle M; Gross E; Schwarz-Boeger U; Pfisterer J; Jonat W; Gerber WD; Albacht B; Fischer B; Schlegelberger B; Arnold N
    Hum Mutat; 2000 Dec; 16(6):529-30. PubMed ID: 11102986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenetic information in the hands of physicians and the preventive options of persons who are not their patients.
    Rigo A; Stuy J
    Ann N Y Acad Sci; 1999; 889():256-61. PubMed ID: 10668503
    [No Abstract]   [Full Text] [Related]  

  • 17. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Informed consent for BRCA1 and BRCA2 testing.
    Rimer BK; Sugarman J; Winer E; Bluman LG; Lerman C
    Breast Dis; 1998 Apr; 10(1-2):99-114. PubMed ID: 15687553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic testing for breast-ovarian cancer susceptibility: a regional trial.
    Loader S; Levenkron JC; Rowley PT
    Genet Test; 1998; 2(4):305-13. PubMed ID: 10464609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.